Related Experiment Video
Updated: Sep 15, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.5K
Renal denervation for managing hypertension: Key elements in selecting and referring patients
Michael A Weber1, Eric A Secemsky2, Anna Krawisz2
1Division of Cardiovascular Medicine, SUNY Downstate Medical Center, Brooklyn, NY, United States of America.
Summary
Renal denervation (RDN) offers a new treatment for uncontrolled high blood pressure. This paper outlines models for integrating RDN referral pathways into healthcare systems to improve patient access and outcomes.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Nephrology
Background:
- Resistant hypertension affects many patients despite lifestyle changes and medication.
- Renal denervation (RDN) is an approved therapy for difficult-to-control hypertension.
- Effective patient referral pathways are crucial for RDN accessibility.
Purpose of the Study:
- To explore program models for integrating RDN into clinical practice.
- To discuss strategies for creating accessible patient referral pathways for RDN.
- To optimize the application of RDN for improved hypertension management.
Main Methods:
- Review of current healthcare system structures for hypertension management.
- Analysis of decentralized and centralized RDN program models.
- Consideration of patient selection criteria and team-based care approaches.
Main Results:
- Checklists can facilitate patient selection in community practices.
- Centralized and decentralized models offer different integration approaches.
- Multidisciplinary teams are key for successful patient selection and RDN program management.
Conclusions:
- Implementing structured RDN referral pathways can enhance patient access to this therapy.
- Careful patient selection by expert teams is vital for RDN efficacy.
- Optimized RDN integration can improve hypertension control and reduce cardiovascular risk.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
513
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
513
01:25Antihypertensive Drugs: Direct Renin Inhibitors
833
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
833
01:16Antihypertensive Drugs: Action of Diuretics
877
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
877
01:23Antihypertensive Drugs: Vasodilators
646
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
646
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
892
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
892
01:17Antihypertensive Drugs: Action of β1 Blockers
614
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
614